Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.0029 | 0.3091 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0068 | 1 | 1 |
Echinococcus granulosus | nuclear factor of activated T cells 5 | 0.006 | 0.8512 | 0.8512 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0029 | 0.3091 | 0.3996 |
Schistosoma mansoni | jun-related protein | 0.0055 | 0.7736 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0029 | 0.3091 | 0.5 |
Echinococcus multilocularis | jun protein | 0.0068 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0029 | 0.3091 | 0.3996 |
Echinococcus granulosus | jun protein | 0.0068 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0055 | 0.7736 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0029 | 0.3091 | 0.3091 |
Onchocerca volvulus | 0.0053 | 0.7404 | 0.5 | |
Entamoeba histolytica | hypothetical protein | 0.0029 | 0.3091 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0066 | 0.9669 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0029 | 0.3091 | 0.3091 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0068 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0053 | 0.7404 | 0.6243 |
Echinococcus multilocularis | nuclear factor of activated T cells 5 | 0.006 | 0.8512 | 0.8512 |
Entamoeba histolytica | hypothetical protein | 0.0029 | 0.3091 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED25 (functional) | = 0.05 mg kg-1 day-1 | Effective dose to reduce 25% of glucose levels in blood | ChEMBL. | 1635060 |
ED25 (functional) | = 0.05 mg kg-1 day-1 | Effective dose to reduce 25% of glucose levels in blood | ChEMBL. | 1635060 |
ED25 (functional) | = 0.1 mg kg-1 day-1 | Effective dose to reduce 25% of triglyceride levels in plasma | ChEMBL. | 1635060 |
ED25 (functional) | = 0.1 mg kg-1 day-1 | Effective dose to reduce 25% of triglyceride levels in plasma | ChEMBL. | 1635060 |
Reduction (functional) | = 54 % | Maximum reduction in blood glucose levels in KKA mice at a dosage of 0.001% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 54 % | Maximum reduction in blood glucose levels in KKA mice at a dosage of 0.001% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 58 % | Maximum reduction in blood glucose levels in KKA mice at a dosage of 0.005% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 58 % | Maximum reduction in blood glucose levels in KKA mice at a dosage of 0.005% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 62 % | Maximum reduction in plasma triglyceride levels in KKA mice at a dosage of 0.001% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 62 % | Maximum reduction in plasma triglyceride levels in KKA mice at a dosage of 0.001% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 81 % | Maximum reduction in plasma triglyceride levels in KKA mice at a dosage of 0.005% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 81 % | Maximum reduction in plasma triglyceride levels in KKA mice at a dosage of 0.005% in diet | ChEMBL. | 1635060 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.